Healios K.K. (OTCMKTS:HLOSF) Short Interest Down 19.8% in July

Healios K.K. (OTCMKTS:HLOSFGet Rating) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 609,100 shares, a drop of 19.8% from the June 30th total of 759,200 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Healios K.K. Trading Down 0.7 %

OTCMKTS HLOSF opened at 14.55 on Thursday. Healios K.K. has a 1 year low of 14.55 and a 1 year high of 14.65.

Healios K.K. Company Profile

(Get Rating)

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.